GDS Wealth Management Boosts Stake in Edwards Lifesciences Corporation $EW

GDS Wealth Management raised its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 4.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 225,998 shares of the medical research company’s stock after buying an additional 9,046 shares during the quarter. GDS Wealth Management’s holdings in Edwards Lifesciences were worth $17,576,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Financial Life Planners purchased a new position in shares of Edwards Lifesciences in the third quarter valued at $93,000. UniSuper Management Pty Ltd lifted its position in Edwards Lifesciences by 29.8% during the third quarter. UniSuper Management Pty Ltd now owns 64,031 shares of the medical research company’s stock valued at $4,980,000 after purchasing an additional 14,695 shares during the last quarter. Jennison Associates LLC grew its stake in shares of Edwards Lifesciences by 19.6% in the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock worth $1,085,574,000 after buying an additional 2,287,783 shares in the last quarter. Westfuller Advisors LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth about $79,000. Finally, Teacher Retirement System of Texas raised its position in shares of Edwards Lifesciences by 88.1% during the 3rd quarter. Teacher Retirement System of Texas now owns 377,974 shares of the medical research company’s stock valued at $29,395,000 after buying an additional 177,010 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on EW shares. BTIG Research reissued a “buy” rating and set a $103.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research note on Thursday, December 4th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Wednesday. Jefferies Financial Group set a $98.00 price target on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Piper Sandler reaffirmed an “overweight” rating and set a $98.00 price objective (up from $95.00) on shares of Edwards Lifesciences in a research note on Tuesday. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $108.00 target price on shares of Edwards Lifesciences in a report on Friday, January 9th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus price target of $96.82.

Edwards Lifesciences Trading Down 0.9%

EW stock opened at $83.70 on Friday. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89. The firm’s 50-day moving average is $84.99 and its 200 day moving average is $80.83. The company has a market capitalization of $48.57 billion, a PE ratio of 36.08, a P/E/G ratio of 3.19 and a beta of 0.95. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the firm earned $0.67 EPS. The company’s revenue for the quarter was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction on Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the transaction, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,885,571.40. This represents a 4.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Scott B. Ullem sold 7,700 shares of the firm’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total value of $650,419.00. Following the transaction, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,370,184.06. This represents a 16.18% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 57,824 shares of company stock worth $4,863,323. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.